There is an unbridled sense of optimism in the HIV prevention field today. There are now two vaccine efficacy trials and an efficacy study of antibodies for HIV prevention ongoing, all of them in Africa. There is also a new generation of HIV vaccine candidates entering clinical trials. These candidates harness the tremendous insights into natural infection and the development of broadly neutralizing antibodies that have been garnered during the last decade. There is also significant progress on another front — the increasingly prominent role African scientists are playing in the quest to develop an HIV vaccine.
Download the special issue of IAVI Report on HIV vaccine science in Africa here.